Test Price
1,800 AEDโ Home Collection Available
Von Willebrand Factor Collagen Binding Activity (vWF:CB) Test in UAE โ Diagnostic Gold Standard for Bleeding Disorders
Executive Summary & Core Metrics
- Diagnostic Precision: 99.9% sensitivity and 99.7% specificity via ISO 9001:2015 accredited chemiluminescent immunoassay (CLIA) validated against LC-MS/MS reference methods.
- Premium Logistics: VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary post-test telephonic consultation for result interpretation and personalised management planning.
- Insurance Verification: Direct billing confirmation via WhatsApp at +971 54 548 8731.
- Turnaround Time: Same-day reporting โ samples received by 11 AM yield results by 6 PM.
Test Overview & Methodology
The vWF:CB assay quantitatively measures the functional capacity of von Willebrand factor to bind collagen, a critical step in platelet adhesion and primary haemostasis. This specialised test is indispensable for differentiating subtypes of von Willebrand disease (VWD), monitoring therapeutic response to DDAVP or VWF concentrates, and evaluating patients with unexplained mucocutaneous bleeding. Results must be interpreted alongside VWF antigen and Factor VIII activity for a complete diagnostic profile.
| Feature | DNA Labs UAE vWF:CB Assay | Standard ELISA Alternative |
|---|---|---|
| Methodology | Chemiluminescent Immunoassay (CLIA) โ validated against LC-MS/MS reference | Colorimetric enzyme-linked immunosorbent assay |
| Diagnostic Precision | 99.9% sensitivity / 99.7% specificity | Approximately 88โ92% sensitivity with lower inter-laboratory reproducibility |
| Turnaround Time | Same-day: sample by 11 AM โ report by 6 PM | 2โ3 working days |
| Price | 1,800 AED | 1,500 โ 2,000 AED (variable) |
Physician Insight & Safety Protocols
Dr. Ajay Singh | General Practitioner | DHA Registration ID: 36234132
โThe vWF:CB activity assay provides essential functional discrimination for accurate subtyping of von Willebrand disease. Low collagen-binding capacity relative to VWF antigen indicates a qualitative multimer defect characteristic of type 2 variants. Clinicians must always correlate laboratory findings with a detailed personal and family bleeding history, as transient reductions can occur during acute-phase inflammatory states. Never interpret vWF:CB results in isolation โ the complete triad of VWF antigen, Factor VIII activity, and collagen binding is mandatory for a definitive diagnosis.โ
Clinical Advisory โ Medication & Sample Integrity
๐ด Critical Safety Considerations
Do not discontinue any prescribed anticoagulant or antiplatelet therapy without explicit instruction from your treating physician. Abrupt cessation may increase thrombotic risk. Always inform the phlebotomist of all medications, including over-the-counter supplements such as fish oil or gingko biloba.
If the whole blood sample cannot be processed to platelet-poor plasma and frozen within one hour of collection, home phlebotomy must not proceed. In such cases, schedule an in-clinic collection to preserve sample integrity and avoid spurious results.
Patient Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Not appropriate for patients with active, life-threatening haemorrhage requiring immediate surgical or medical intervention. Individuals on high-intensity anticoagulation (e.g., warfarin with INR exceeding 3.5) should defer elective testing until stabilised under medical supervision.
- Emergency Warning Signs โ Seek immediate emergency care (call 998) if you experience: sudden, severe uncontrolled bleeding; large unexplained bruises appearing without trauma; blood in urine or black, tarry stools; vomiting blood; or sudden severe headache accompanied by visual disturbances.
Patient FAQ & Clinical Guidance
1. What is the Von Willebrand Factor Collagen Binding Activity (vWF:CB) test?
The vWF:CB test quantifies the functional ability of von Willebrand factor to bind collagen, a critical step in platelet plug formation and primary haemostasis. It is primarily ordered to differentiate subtypes of von Willebrand disease, particularly to distinguish type 1 (quantitative deficiency) from type 2 variants (qualitative defects). A reduced vWF:CB-to-VWF antigen ratio is the hallmark of type 2A, 2B, or 2M disease, while type 3 shows undetectable activity. This test is routinely performed alongside VWF antigen and Factor VIII activity for a comprehensive haemostatic profile.
2. How should I prepare for the vWF:CB blood draw, and does fasting affect results?
Overnight fasting for at least eight hours is strongly recommended because lipemic samples can interfere with the chemiluminescent immunoassay detection system. You may drink plain water during the fasting period. Avoid strenuous physical exercise for 24 hours before the test, as acute exertion temporarily elevates VWF levels. Continue all prescribed medications unless your doctor specifically advises otherwise. For home collection, our trained phlebotomist will ensure immediate gentle inversion of the citrate tube and initiate cold-chain transport within the required window.
3. Why is the CLIA-based vWF:CB assay superior to standard ELISA, and when is it clinically indicated?
The CLIA method offers superior analytical sensitivity and broader dynamic range compared to traditional colorimetric ELISA, enabling precise quantification across the full spectrum of VWF activity โ from undetectable in type 3 disease to elevated in inflammatory states. It directly measures the collagen-binding function of high-molecular-weight VWF multimers, which are the most haemostatically active. This functional insight is essential before surgical procedures, in evaluating unexplained menorrhagia, when monitoring desmopressin (DDAVP) therapy, and for accurate classification of VWD subtypes to guide appropriate treatment strategies.
4. What sample type is required, and how is it collected and transported?
The required specimen is 3 mL of whole blood collected into one light blue-top sodium citrate tube (3.2% buffered citrate). The tube must be gently inverted five to six times immediately after collection to ensure proper anticoagulation. For in-clinic draws, transport the sample to the laboratory at 2โ8ยฐC within four hours. If four-hour transport is not feasible, platelet-poor plasma must be prepared within one hour: centrifuge at 3600 rpm for 15 minutes, transfer supernatant, re-centrifuge, and freeze the final plasma immediately at -20ยฐC or lower. Ship frozen and do not thaw until testing. Our medical courier service follows this protocol rigorously for every home collection.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with UAE federal legislation governing health data protection and diagnostic laboratory practice.
- Personal Data Protection: All patient information is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring confidential handling, lawful collection, and secure storage of health-related personal data.
- Health Information Technology: Our laboratory information systems and electronic health record interfaces comply with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, maintaining data integrity and cybersecurity standards.
- Medical Liability Framework: Clinical testing protocols, patient consent procedures, and sample handling workflows adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, safeguarding patient rights and ensuring diagnostic accountability.
- Accreditation: Our facility maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139), affirming our commitment to rigorous quality management in all pre-analytical, analytical, and post-analytical processes.
Clinical & Logistical Metadata
| Test Name | Von Willebrand Factor Collagen Binding Activity (vWF:CB) |
| Price (AED) | 1,800 AED |
| Turnaround Time | Same-day: samples received by 11 AM yield results by 6 PM |
| Sample Type / Matrix | Whole blood โ 3 mL in sodium citrate (light blue-top tube); platelet-poor plasma if shipping frozen |
| Methodology Used | Chemiluminescent Immunoassay (CLIA) validated against LC-MS/MS reference |
| ICD-10-CM Code | D68.0 |
| LOINC Code | 31647-8 |
| DHA Facility License & Laboratory Address | License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians